Émilie De Carli

Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5

Christelle Dufour, Stéphanie Foulon, Anne Geoffray et al. · Neuro-Oncology · 2020 · 55 citations · Full text

Medicine, Oncology, Pediatrics +17

VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the Société Française des Cancers de l'Enfant (SFCE)

Franck Bourdeaut, Émilie De Carli, Carole Coze et al. · Pediatric Blood & Cancer · 2009 · 47 citations

Medicine, Oncology, Pathology +12

Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy

Josué Rakotonjanahary, Émilie De Carli, Matthieu Delion et al. · PLoS ONE · 2015 · 44 citations · Full text

Medicine, Oncology, Pediatrics +17

First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial

Raphael J. Morscher, Caroline Brard, Pablo Berlanga et al. · European Journal of Cancer · 2021 · 37 citations · Full text

Medicine, Oncology, Pharmacology +15

Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?

María-Jesús Lobón-Iglesias, G Giraud, David Castel et al. · Journal of Neuro-Oncology · 2017 · 26 citations

Medicine, Neurology, Oncology +8